ET
MLYS icon

Entropy Technologies’s Mineralys Therapeutics MLYS Stock Holding History

Entropy Technologies’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$276K Sell
10,180
-5,995
-37% -$176K 0.01% 724
2025
Q4 		$587K Buy
+16,175
New +$649K 0.03% 518

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Entropy Technologies's MLYS Position: Q1 2026 in Review

Entropy Technologies reduced its Mineralys Therapeutics (MLYS) stake by 37% in Q1 2026, selling an estimated $176K and leaving 10,180 shares worth $276K. The position accounts for 0.01% of the portfolio, ranked #724.

Entropy Technologies first reported a position in MLYS in Q4 2025 and has held it in 2 quarters since. The position peaked at $587K in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Entropy Technologies held 10,180 shares of Mineralys Therapeutics worth $276K as of Q1 2026.
  • Entropy Technologies sold 5,995 Mineralys Therapeutics shares in Q1 2026, an estimated $176K.
  • Mineralys Therapeutics made up 0.01% of Entropy Technologies's portfolio in Q1 2026, its #724 holding.
  • Entropy Technologies first reported a position in Mineralys Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Entropy Technologies's Mineralys Therapeutics position peaked at $587K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Entropy Technologies's 13F filing for Q1 2026, filed 14 May 2026.